Drugs / B007
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05668403 | Mar 2023 → Dec 2026 expected | idiopathic membranous glomerulonephritis | Shanghai Jiaolian Drug Research and Development Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06470191 | Jul 2024 → Dec 2026 expected | idiopathic membranous glomerulonephritis | Shanghai Jiaolian Drug Research and Development Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06454357 | Jul 2024 → Dec 2026 expected | pemphigus | Shanghai Jiaolian Drug Research and Development Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06447597 | Jul 2024 → Jun 2026 overdue | generalized myasthenia gravis | Shanghai Jiaolian Drug Research and Development Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05668403 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-CD20 Monoclonal Antibody” NCT05668403 ↗ |
| Route | Subcutaneous | “350mg Subcutaneous injection was administered on days 1 and 15” NCT05668403 ↗ |